1166 related articles for article (PubMed ID: 10327070)
21. Chemotherapy and pregnancy.
Leslie KK
Clin Obstet Gynecol; 2002 Mar; 45(1):153-64. PubMed ID: 11862066
[No Abstract] [Full Text] [Related]
22. Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells.
Seoane S; Montero JC; Ocaña A; Pandiella A
J Natl Cancer Inst; 2010 Sep; 102(18):1432-46. PubMed ID: 20811002
[TBL] [Abstract][Full Text] [Related]
23. Interactions of doxycycline with chemotherapeutic agents in human breast adenocarcinoma MDA-MB-231 cells.
Foroodi F; Duivenvoorden WC; Singh G
Anticancer Drugs; 2009 Feb; 20(2):115-22. PubMed ID: 19209028
[TBL] [Abstract][Full Text] [Related]
24. 3,3'-diindolylmethane and paclitaxel act synergistically to promote apoptosis in HER2/Neu human breast cancer cells.
McGuire KP; Ngoubilly N; Neavyn M; Lanza-Jacoby S
J Surg Res; 2006 May; 132(2):208-13. PubMed ID: 16580691
[TBL] [Abstract][Full Text] [Related]
25. Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models.
Agus DB; Scher HI; Higgins B; Fox WD; Heller G; Fazzari M; Cordon-Cardo C; Golde DW
Cancer Res; 1999 Oct; 59(19):4761-4. PubMed ID: 10519379
[TBL] [Abstract][Full Text] [Related]
26. Current and planned clinical trials with trastuzumab (Herceptin).
Baselga J
Semin Oncol; 2000 Oct; 27(5 Suppl 9):27-32. PubMed ID: 11049054
[TBL] [Abstract][Full Text] [Related]
27. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
Dank M
Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
[TBL] [Abstract][Full Text] [Related]
28. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
Xu F; Leadon SA; Yu Y; Boyer CM; O'Briant K; Ward K; McWatters A; Zhao X; Bae DS; DeSombre K; Zalutsky MR; Bast RC
Clin Cancer Res; 2000 Aug; 6(8):3334-41. PubMed ID: 10955821
[TBL] [Abstract][Full Text] [Related]
29. Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin beta-2.
Harris LN; Yang L; Tang C; Yang D; Lupu R
Clin Cancer Res; 1998 Apr; 4(4):1005-12. PubMed ID: 9563896
[TBL] [Abstract][Full Text] [Related]
30. Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo.
Spänkuch B; Heim S; Kurunci-Csacsko E; Lindenau C; Yuan J; Kaufmann M; Strebhardt K
Cancer Res; 2006 Jun; 66(11):5836-46. PubMed ID: 16740723
[TBL] [Abstract][Full Text] [Related]
31. [Chemosensitivity test for 170 human breast carcinoma samples].
He Z; Yuan J; Chen Z; Liu S; Shen Z; Fei H
Hunan Yi Ke Da Xue Xue Bao; 1998; 23(6):531-4. PubMed ID: 10806759
[TBL] [Abstract][Full Text] [Related]
32. Survival of tumor cells in stem cell preparations and bone marrow of patients with high-risk or metastatic breast cancer after receiving dose-intensive or high-dose chemotherapy.
Kasimir-Bauer S; Mayer S; Bojko P; Borquez D; Neumann R; Seeber S
Clin Cancer Res; 2001 Jun; 7(6):1582-9. PubMed ID: 11410494
[TBL] [Abstract][Full Text] [Related]
33. HER2/neu antisense targeting of human breast carcinoma.
Roh H; Pippin JA; Green DW; Boswell CB; Hirose CT; Mokadam N; Drebin JA
Oncogene; 2000 Dec; 19(53):6138-43. PubMed ID: 11156527
[TBL] [Abstract][Full Text] [Related]
34. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
35. Trastuzumab enhances the anti-tumor effects of the histone deacetylase inhibitor sodium butyrate on a HER2-overexpressing breast cancer cell line.
Chen W; Wei F; Xu J; Wang Y; Chen L; Wang J; Guan X
Int J Mol Med; 2011 Dec; 28(6):985-91. PubMed ID: 21887460
[TBL] [Abstract][Full Text] [Related]
36. The immunocytokine scFv23/TNF targeting HER-2/neu induces synergistic cytotoxic effects with 5-fluorouracil in TNF-resistant pancreatic cancer cell lines.
Lyu MA; Kurzrock R; Rosenblum MG
Biochem Pharmacol; 2008 Feb; 75(4):836-46. PubMed ID: 18082672
[TBL] [Abstract][Full Text] [Related]
37. [Adjuvant chemotherapy for breast cancer and targeted therapies].
Dufresne A; Bachelot T; Blay JY
Rev Prat; 2008 Mar; 58(5):477-8. PubMed ID: 18524101
[No Abstract] [Full Text] [Related]
38. Combined radioimmunotherapy and chemotherapy of breast tumors with Y-90-labeled anti-Her2 and anti-CEA antibodies with taxol.
Crow DM; Williams L; Colcher D; Wong JY; Raubitschek A; Shively JE
Bioconjug Chem; 2005; 16(5):1117-25. PubMed ID: 16173788
[TBL] [Abstract][Full Text] [Related]
39. New combinations with Herceptin in metastatic breast cancer.
Winer EP; Burstein HJ
Oncology; 2001; 61 Suppl 2():50-7. PubMed ID: 11694788
[TBL] [Abstract][Full Text] [Related]
40. Rational combinations of siRNAs targeting Plk1 with breast cancer drugs.
Spänkuch B; Kurunci-Csacsko E; Kaufmann M; Strebhardt K
Oncogene; 2007 Aug; 26(39):5793-807. PubMed ID: 17369857
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]